Europe Facial Injectable Market Size was valued at USD 2.1 Billion in 2022. The Europe Facial Injectable Market industry is projected to grow from USD 2.26 Billion in 2023 to USD 4.13 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.80% during the forecast period (2023 - 2032).The increase in cosmetic operations and aesthetic awareness, the ageing of the population, the development of affordable face injectables, are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The cosmetics industry has grown significantly over the last ten years. There has been an increase in the overall number of non-surgical operations, such as wrinkle relaxer and dermal filler injections, due to the rise in aesthetic attractiveness and accessibility of highly complex cosmetic procedures. This advancement can largely be attributed to the advantages of technology, such as short recovery times, reduced infection risks, less blood loss, and decreased overall procedural costs. For instance, according to data from the International Society of Aesthetic Plastic Surgery (ISAPS), more than 10,129,528 cosmetic surgical procedures were performed in 2021. The most common non-surgical procedures in 2021 will be calcium hydroxylapatite (222,785), poly-L-lactic acid (121,087), botulinum toxin, and hyaluronic acid. The market is expected to increase throughout the forecast period due to the large number of facial injectable procedures.
The geriatric population is also steadily growing, which supports the market's expansion. For instance, one in six individuals worldwide will be 60 years of age or older by 2030, predicts the WHO estimate from 2021. By 2050, there will be 1.4 billion persons in this age group, up from 1 billion in 2020. There will be 2.1 billion persons over the age of 60 in the world by 2050. The number of adults 80 and older is projected to treble between 2020 and 2050, reaching 426.0 million. Growing the geriatric population is projected to support the market's growth over the forecast period because this generation is the primary target for cosmetic operations. Thus, driving the Europe Facial Injectable Market revenue.
The Europe Facial Injectable Market segmentation, based on type includes Hyaluronic Acid, Collagen, Botulinum Toxin, and Polymers & Particles (PPFS). With 34% of market revenue ($0.98 billion) coming from the hyaluronic acid category, the market was dominated by this product. Hyaluronic acid-based solutions are increasingly in demand, partly due to their relative safety and longevity.
The Europe Facial Injectable Market segmentation, based on application, includes Facial Surgery, Facial Uplift and Others. The category that brought in the most money (60.4%) was face uplift. The significant presence of well-known businesses that cater to patients' needs and raise knowledge about how successful these treatments are at reducing lines and wrinkles is credited with the segment's rise.
The Europe Facial Injectable Market segmentation, based on end user, includes Hospitals, Clinics, and Research & Development Facilities. The hospital category produced the largest revenue (46.4%). These operations, for instance, are provided by a number of hospitals and outpatient surgical facilities in the United Kingdom to address a variety of skin issues, such as the typical ageing indicators that appear around the forehead and eyes, such as frown lines, laughter lines, and crow's feet. During the forecast period, it is predicted that the others segment would expand at a slower CAGR.
Figure 1: Europe Facial Injectable Market, by End User, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Facial Injectable Regional Insights
By region, the study provides the market insights into Europe. Europe Facial Injectable Market accounts for the second-largest market share. This is a result of the substantial volume of cosmetic processes and heavy spending on R&D efforts by significant market players. Further, the German Europe Facial Injectable Market held the largest market share, and the UK Europe Facial Injectable Market was the fastest growing market in the European region.
Figure 2: EUROPE FACIAL INJECTABLE MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Germany dominated the region. Germany has a robust economy, which allows its citizens to have higher disposable incomes. This financial stability has enabled more people to afford facial injectable treatments, contributing to market growth.
France held the second largest regional share. France attracts a significant number of cosmetic tourists seeking aesthetic treatments. Many people travel to France specifically for cosmetic procedures, including facial injectables, due to the country's renowned expertise in the field. This influx of tourists has boosted the demand for facial injectables in the French market.
Facial Injectable Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Europe Facial Injectable Market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Facial Injectable industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Facial Injectable industry to benefit clients and increase the market sector. In recent years, the Facial Injectable industry has offered some of the most significant advantages to medicine. Major players in the Europe Facial Injectable Market, including Allergan Inc (Ireland), Merz Pharma (Germany), Ipsen (France), Valeant Pharmaceuticals (Canada), Galderma (Switzerland), Integra Lifesciences (Us), Tei Biosciences, Fibrogen (Finland), and Ethicon (Us), are attempting to increase market demand by investing in research and development operations.
Gavin S. Herbert, a chemist, created the pharmaceutical business Allergan in 1948. It merged with Irish pharmaceutical company Actavis plc in 2015 to form Allergan plc, an American company with Irish headquarters that develops, produces, and sells brand-name drugs and medical devices for the central nervous system, gastroenterology, medical aesthetics, and eye care. Allergan joined AbbVie in 2023, a multinational pharmaceutical corporation with a focus on the development, production, and marketing of branded pharmaceutical, device, biologic, and biosimilar medicines. The 60+ illnesses that Allergan treats with its more than 30 products range from oncology and immunology to cosmetics and eye care. They produce a range of pharmaceutical goods, including Botox, which has both therapeutic and aesthetic uses. A division of Allergan, Allergan Aesthetics creates, produces, and sells a range of premium brands and goods for the face, body, cosmetic surgery, and skin care.
Founded in Frankfurt, Germany, Merz Pharma is a privately held pharmaceutical firm with affiliates throughout Europe, the US, Canada, Mexico, Brazil, and Asia Pacific. Regional offices are also located in Singapore and North Carolina, USA. The business engages in product discovery, research, and distribution for neurologically induced movement disorders and aesthetic medicine. One of the pioneers in aesthetic medicine, Merz Aesthetics offers a wide range of cutting-edge skin care products. The mission of Merz Therapeutics is to meet the special requirements of those with mobility problems, neurological illnesses, and other medical issues. With its tetesept and Merz Spezial brands, Merz Consumer Care sells items for health, wellness, and beauty. The business has devoted more than 110 years to creating technologies that enhance patients' quality of life and health. The three businesses Merz Aesthetics, Merz Therapeutics, and Merz Consumer Care make up the multinational, family-owned corporation Merz.
Key Companies in the Europe Facial Injectable Market include
April 2022:For the treatment of moderate to severe glabellar lines, Revance Therapeutics, Inc.'s resubmitted Biologics Licence Application (BLA) for DaxibotulinumtoxinA was accepted by the FDA.
March 2022:A firm owned by AbbVie, Allergan Aesthetics, introduced HArmonyCa with lidocaine in Europe. Hyaluronic acid and calcium hydroxyapatite are the two active components in this hybrid dual-effect injection.
February 2022:The purchase of Viora was announced by Sinclair Pharma. The company is able to grow its footprint in the market for medical aesthetics products thanks to this acquisition.
December 2021:In order to expand Allergan Aesthetics' line of non-invasive body contouring treatments to include a treatment for the appearance of cellulite, the company successfully completed its acquisition of Soliton, Inc.
September 2021:An exclusive deal has been announced by Galderma and Sofregen to create the following generation of biostimulator fillers.
Hyaluronic Acid
Collagen
Botulinum Toxin
Polymers and Particles(PPFS)
Hospitals
Clinics
Research and Development Facilities
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 2.1 Billion |
| Market Size 2023 | USD 2.26 Billion |
| Market Size 2032 | USD 4.13 Billion |
| Compound Annual Growth Rate (CAGR) | 7.80% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, End User, and Region |
| Geographies Covered | Europe |
| Countries Covered | German, France, UK, Italy, Spain, |
| Key Companies Profiled | Allergan Inc (Ireland), Merz Pharma (Germany), Ipsen (France), Valeant Pharmaceuticals (Canada), Galderma (Switzerland), Integra Lifesciences (Us), Tei Biosciences, Fibrogen (Finland), Ethicon (Us) |
| Key Market Opportunities | The rising aesthetic consciousness and number of cosmetic procedures |
| Key Market Dynamics | The introduction of cost-effective facial injectables, and the aging population |
Frequently Asked Questions (FAQ) :
The Europe Facial Injectable Market size was valued at USD 2.1 Billion in 2022.
The market is projected to grow at a CAGR of 7.80% during the forecast period, 2023-2032.
Germany had the largest share in the market
The key players in the market are Allergan Inc (Ireland), Merz Pharma (Germany), Ipsen (France), Valeant Pharmaceuticals (Canada), Galderma (Switzerland), Integra Lifesciences (Us), Tei Biosciences, Fibrogen (Finland), Ethicon (Us).
The hyaluronic acid category dominated the market in 2022.
The hospitals had the largest share in the market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
